A Randomised, Placebo-controlled, Double-blind Phase II of Sequential Administration of Tarceva (Erlotinib) or Placebo in Combination With Gemcitabine/Platinum as First-line Treatment in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC).
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2015
At a glance
- Drugs Erlotinib (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms FAST-ACT
- Sponsors Roche
- 05 Dec 2013 New source identified and integrated: ClinicalTrials.gov record.
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche.
- 08 Sep 2009 Results published in the Journal of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History